Format

Send to

Choose Destination
Nat Rev Neurosci. 2018 Nov;19(11):655-671. doi: 10.1038/s41583-018-0070-8.

CNS infection and immune privilege.

Author information

1
Division of Applied Medicine, Section of Immunology and Infection, Institute of Medical Sciences, University of Aberdeen, Scotland, UK. j.forrester@abdn.ac.uk.
2
Immunology and Virology Program, Centre for Ophthalmology and Visual Science, University of Western Australia, Crawley, Western Australia, Australia. j.forrester@abdn.ac.uk.
3
Centre for Experimental Immunology, Lions Eye Institute, Nedlands, Western Australia, Australia. j.forrester@abdn.ac.uk.
4
Department of Anatomy and Developmental Biology, Monash Biomedicine Discovery Institute, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.

Abstract

Classically, the CNS is described as displaying immune privilege, as it shows attenuated responses to challenge by alloantigen. However, the CNS does show local inflammation in response to infection. Although pathogen access to the brain parenchyma and retina is generally restricted by physiological and immunological barriers, certain pathogens may breach these barriers. In the CNS, such pathogens may either cause devastating inflammation or benefit from immune privilege in the CNS, where they are largely protected from the peripheral immune system. Thus, some pathogens can persist as latent infections and later be reactivated. We review the consequences of immune privilege in the context of CNS infections and ask whether immune privilege may provide protection for certain pathogens and promote their latency.

PMID:
30310148
DOI:
10.1038/s41583-018-0070-8

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center